Valantine Hannah

DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed Jun 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$342K
Net Open-Market Flow
-$342K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 23, 2026Sell(S)2K$68.57$151K9K
Jun 22, 2026Grant(A)4K$011K
Jun 22, 2026Option exercise(M)3K$41.73$117K14K
Jun 22, 2026Sell(S)3K$68.00$191K11K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 22, 2026Grant(A)5K$05K
Jun 22, 2026Option exercise(M)3K$06K

Transaction Codes

S
Open-market sale
A
Grant / award
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000635) within minutes of acceptance. Every field above traces to the original document. Verify it directly: